XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsWhat do oncologists need to know about biosimilar products?Growth factor use in medication-induced hematologic toxicity.First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Management of neutropenia in cancer patients.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisA randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyA thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and DocetaxelA randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationSide effects of cytokines approved for therapy.Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Tbo-Filgrastim: A Review in Neutropenic Conditions.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical OncKey concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.Follow-on biologics in oncology - the need for global and local regulations.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Biosimilar rhG-CSFs: how similar are they?Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.
P2860
Q24198118-27B5B449-CDB2-4C8F-84AF-1969BDA21741Q27008080-A3C05574-57D2-4321-BD3C-7FD101E0C445Q28071687-522E00A9-C715-4BCC-9DCC-A1CD938B9C96Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1AQ33420907-02DF99A8-3589-4E51-A495-97DE7181C9D4Q33756369-41D5E394-78CA-421A-9FC8-248C9AE823A5Q33762775-266F6745-4AA1-49AD-B3B4-896D828746B0Q34029496-D2794113-91E4-4108-8754-2E26AB74E780Q34333814-C4B32BEA-E8A0-4721-8F1A-4AFFEAB6D811Q34941030-24ED3534-57AA-4CF3-A82D-D21EF3D67789Q35633293-8E084CE0-3ABD-4D29-AA55-AAE7B700D4AEQ35835005-9ADA2066-E036-4C7C-BF23-D49C88DEA51BQ36000209-FBBAEB82-68D9-47EE-B378-E4E10D7F3097Q36452230-6C9DB5D3-5C16-4B8C-9B39-721D41C43CF9Q36615056-E5697BCF-AAE3-47A5-87DC-3FB18B968BE6Q36981948-3A8D661D-61B3-4CC1-91CE-D6F2EA900F88Q37205943-15EB6DB1-26CE-4F47-93FD-DE179330C6D9Q37616966-152F8781-ACE2-448D-89A7-737282EEB89FQ37675627-3A72488B-7B63-4D3E-824C-8EAB4E81DD1EQ38082542-7FCB92A1-6C9C-4452-A34E-3704D0D87082Q38125609-D33FC04F-14E2-411F-AF79-6A55314BDE27Q38186025-BC8DB2E2-1FF0-4A23-BE3D-1F891D1FFEC7Q38255698-5E424B28-6AA2-48D5-9FDB-164C4A54B803Q38726241-9F9CA5C2-321B-4133-9727-A7E14B6D35C1Q38749061-D5E129D6-7BF3-4B39-95CC-EB43CDBB7CD2Q38792513-88A579FF-2349-44BC-80DE-C112DBEF8E58Q38969947-0F7FBA17-0846-42EF-8714-A93EA32AA495Q40094120-D7E79F42-9FD3-47F7-BA68-76FB09C72B64Q40245653-A4586042-1549-455A-B346-C101E81B3AA6Q40402240-3B97F0E4-A713-492F-8221-2309D2C37D1FQ42223844-29C838F3-EAB3-4F78-8EB7-3FB0E35C7201Q42783302-B1BAFA52-287A-43DE-88F1-27C8BFAEA535Q43121123-9F9EFD89-E6ED-437D-8C69-F8BA754C8A8DQ44894394-6C66C102-95D8-4D65-9AD9-F2AAA9CE7876Q45788056-C96DB9C7-A05B-4A3A-AB88-6EF713062675Q47213188-83C4B40A-E323-4F21-B20A-3517206F7C17Q47938059-ACBA1FE2-E4B3-4B25-9896-1473B9AB23CCQ48273553-BEED1448-D72D-4D1A-959D-E02F046AA008Q50001689-BB7448D4-684F-40D1-9018-64844C87E828Q50042993-3C50F0B8-0469-4B09-8341-26FC42748442
P2860
XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@en
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@nl
type
label
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@en
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@nl
prefLabel
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@en
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@nl
P2093
P2860
P921
P356
P1433
P1476
XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.
@en
P2093
A del Giglio
D Ganea-Motan
P2860
P2888
P356
10.1186/1471-2407-8-332
P407
P577
2008-11-12T00:00:00Z
P5875
P6179
1014393182